NCT02553577 is a clinical trial in Immune Response, sponsored by Kristin Ashford.

Who is sponsoring NCT02553577?

NCT02553577 is sponsored by Kristin Ashford.

What condition does NCT02553577 study?

NCT02553577 studies Immune Response, Birth Weight, Gestational Age.

Is NCT02553577 still recruiting?

NCT02553577 is currently completed. Last updated 7 July 2021.

Last reviewed 2021-07-07 · How we verify

NCT02553577

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Electronic Cigarettes on Perinatal Immune Responsiveness and Birth Outcomes

Completed Last updated 7 July 2021

What this trial tests

trial in Immune Response in 278 participants. Completed in 28 February 2021.

Timeline

13 January 2016

Primary endpoint
28 February 2021

28 February 2021

Quick facts

Lead sponsor	Kristin Ashford
Status	Completed
Study type	OBSERVATIONAL
Enrollment	278
Start date	13 January 2016
Primary completion	28 February 2021
Estimated completion	28 February 2021
Sites	1 location across United States

Conditions studied

Immune Response — all drugs for Immune Response →
Birth Weight — all drugs for Birth Weight →
Gestational Age — all drugs for Gestational Age →

Sponsor

Kristin Ashford

Who can join

Adults 18 to 44, female only, with Immune Response or Birth Weight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There has been a dramatic escalation of electronic cigarette (e-cig) use among women of childbearing age, including pregnant women. The overall goal of this study is to determine the effects of e-cigs on prenatal biomarkers and birth outcomes. It is imperative that more data about these effects be available to better inform women of childbearing age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Immune Response

Currently open trials in the same condition.

NCT07517068 — The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude · EARLY_PHASE1 · active not recruiting
NCT07178483 — Evaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure · active not recruiting
NCT06512896 — Clinical Study on Intraluminal Injection of FOLactis · NA · recruiting
NCT03875703 — Post-Vaccination Biological Collection · recruiting

Other Kristin Ashford trials

Trials by the same sponsor.

NCT03796208 — Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women · NA · completed
NCT03442530 — Tobacco Use in Pregnancy Intervention for Cessation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02553577 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kristin Ashford
Last refreshed: 7 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02553577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing